A burning heart: combined therapy of checkpoint-inhibitors and prednisolone in a patient with sarcoidosis
Open Access
- 1 January 2024
- journal article
- research article
- Published by OAE Publishing Inc. in The Journal of Cardiovascular Aging
- Vol. 4 (1)
Abstract
Patients with prior autoimmune diseases such as sarcoidosis require special care when treated with checkpoint inhibitors (CPIs), given the risk for reactivation of inflammation. Here, we address the clinical dilemma of initiating CPIs for recurrent metastatic carcinoma in a patient with extensive sarcoidosis, controlled after prolonged immunosuppressive therapy when the tumor recurrence was detected. To achieve the best possible outcome, the case was discussed by an interdisciplinary team comprising specialists in rheumatology, oncology, and CPI-related myocarditis. Literature on this topic was very limited. Based on the pharmacodynamics of CPIs and the pathophysiology of CPI-related autoimmune diseases, we concluded that initiating CPIs alongside low-dose prednisolone would effectively suppress any reactivation of sarcoidosis without interfering with CPIs in a relevant way.Keywords
This publication has 6 references indexed in Scilit:
- Potential Novel Therapeutic Target to Improve Graft Survival: New Insights Into the Role of Checkpoint Molecules in Heart Transplant RejectionCirculation: Heart Failure, 2021
- Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanismsJournal of Clinical Investigation, 2021
- Autoimmunity in Acute Myocarditis: How Immunopathogenesis Steers New Directions for Diagnosis and TreatmentCurrent Cardiology Reports, 2020
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyThe Lancet Oncology, 2018
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditisThe Lancet, 2018
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersJAMA Oncology, 2016